乙型肝炎病毒和丙型肝炎病毒感染对霍奇金淋巴瘤和非霍奇金淋巴瘤患者的影响。
The impact of hepatitis B virus and hepatitis C virus infections in patients with Hodgkin's and non-Hodgkin's lymphoma.
机构信息
Clinical Pathology Department and Microbiology Lab, National Cancer Institute, Cairo University, Cairo, Egypt.
Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
出版信息
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231207342. doi: 10.1177/03946320231207342.
BACKGROUND
This study aimed to determine the prevalence of HCV and occult HBV among newly diagnosed pre-treatment Egyptian lymphoma patients and evaluate patients' outcomes based on the presence of the viral infections.
METHODS
The study included 80 therapy-naïve lymphoma patients including 71 non-Hodgkin lymphoma (NHL) and 9 Hodgkin lymphoma disease (HD) in addition to 100 healthy volunteers. HBV screening using HBsAg and anti-HBc IgM and HCV using AB/Ag ELISA and real-time RT-PCR were screened in tested and control groups. The diagnosis was confirmed by histopathology. Overall survival (OS) and progression-free survival (PFS) were conducted to diseased patients.
RESULTS
Healthy patients showed 4/100, (4%) active HCV infection and 1/100, (1%) active HBV infection and no occult HBV infection. Among NHL patients, 28 were positive for HBV (6 active and 22 occult HBV infection). Occult HBV was also detected in 5/9 HD patients. HCV was detected in (30/71, 42.3%) of NHL patients and in a single HD patient. Ten occult HBV NHL patients showed a mixed infection with HCV. The incidence of both HCV and HBV are higher in NHL than HL patients. After antitumor treatment, complete remission for lymphoma was achieved in 45% of patients. Both overall survival (OS) and progression-free survival (PFS) were correlated and significantly associated with patients' LDH levels.
CONCLUSIONS
Our findings claim the suggestive role of HCV and occult HBV infections in NHL but not HL patients in comparison to healthy control, suggesting pre-screening of related factors including occult HBV in for potential better therapy response.
背景
本研究旨在确定新诊断的埃及淋巴瘤患者中 HCV 和隐匿性乙型肝炎病毒（HBV）的流行率，并根据病毒感染情况评估患者的结局。
方法
研究纳入 80 例初治淋巴瘤患者，包括 71 例非霍奇金淋巴瘤（NHL）和 9 例霍奇金淋巴瘤（HD），以及 100 例健康志愿者。在实验组和对照组中，使用 HBsAg 和抗-HBc IgM 筛查 HBV，使用 AB/Ag ELISA 和实时 RT-PCR 筛查 HCV。通过组织病理学诊断确认诊断。对患病患者进行总生存期（OS）和无进展生存期（PFS）分析。
结果
健康患者中，4/100（4%）存在活动性 HCV 感染，1/100（1%）存在活动性 HBV 感染，无隐匿性 HBV 感染。在 NHL 患者中，28 例 HBV 阳性（6 例活动性和 22 例隐匿性 HBV 感染）。5/9 例 HD 患者也检测到隐匿性 HBV。71 例 NHL 患者中，30 例（42.3%）HCV 阳性，1 例 HD 患者 HCV 阳性。10 例隐匿性 HBV NHL 患者同时感染 HCV。NHL 患者中 HCV 和 HBV 的感染率均高于 HL 患者。经过抗肿瘤治疗，45%的患者达到了淋巴瘤完全缓解。总生存期（OS）和无进展生存期（PFS）均相关，并与患者的 LDH 水平显著相关。
结论
与健康对照组相比，我们的研究结果表明，HCV 和隐匿性 HBV 感染在 NHL 患者中具有提示作用，但在 HL 患者中没有提示作用，提示在进行潜在的更好治疗反应时，应预先筛查包括隐匿性 HBV 在内的相关因素。
Zotero 插件